

#3

SLR:dm 08/09/05 5585-70346-01 41785 P100558US

Rec'd PCT/PTO 11 AUG 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:**

Claire Lewis and Carolyn Staton

**Application No.** 10/521,974

**Filed:** January 21, 2005

**Confirmation No.** 6738

**For:** INHIBITION OF CELL DIVISION BASED  
USE OF ANALOGS OF NEUROPEPTIDE Y

**Examiner:** Not yet assigned

**Art Unit:** Not yet assigned

**Attorney Reference No.** 5585-70346-01

**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Date Mailed August 9, 2005

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

cc: Docketing

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Attorney Docket Number	5585-70346-01
				Application Number	10/521,974
				Filing Date	January 21, 2005
				First Named Inventor	Lewis
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
<b>FOREIGN PATENT DOCUMENTS</b>					
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>Country</b>	<b>Number</b>	<b>Publication Date</b>	<b>Name of Applicant or Patentee</b>
		WIPO	WO 95/00161 A1	05.01.1995	University of Cincinnati
		WIPO	WO 02/051857 A1	04.07.2002	Genaissance Pharmaceuticals, Inc.
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>			
		Behr and Goldenberg, "Improved Prospects for Cancer Therapy with Radiolabeled Antibody Fragments and Peptides?," <i>J. Nucl. Med.</i> 37:834-836 (1996).			
		Gehlert, "Subtypes of Receptors for Neuropeptide Y: Implications for the Targeting of Therapeutics," <i>Life Sci.</i> 55:551-562 (1994).			
		Michel et al., "XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors," <i>Pharmacol. Rev.</i> 50:143-150 (1998).			
		Minth et al., "Cloning, Characterization, and DNA Sequence of a Human cDNA Encoding Neuropeptide Tyrosine," <i>Proc. Natl. Acad. Sci. USA</i> 81:4577-4581 (1984).			
		Reubi et al., "Y <sub>1</sub> - Mediated Effect of Neuropeptide Y in Cancer: Breast Carcinomas as Targets," <i>Cancer Res.</i> 61:4636-4641 (2001).			
		Wahlestedt and Reis, "Neuropeptide Y-Related Peptides and Their Receptors--Are the Receptors Potential Therapeutic Drug Targets?," <i>Annu. Rev. Pharmacol. Toxicol.</i> 32:309-352 (1993).			
		Yu et al., "Vitamin E and the Y4 Agonist BA-129 Decrease Prostate Cancer Growth and Production of Vascular Endothelial Growth Factor," <i>J. Surg. Res.</i> 105:65-68 (2002).			

EXAMINER  
SIGNATURE:DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.